Form 4: Calidi CFO Granted 30,000 Stock Options

Calidi Biotherapeutics' Chief Financial Officer, Andrew C. Jackson, received a grant of 30,000 incentive stock options at an exercise price of $1.58.

Summary

• Andrew C. Jackson, Chief Financial Officer of Calidi Biotherapeutics, Inc. (CLDI), was granted 30,000 incentive stock options.
• The options were granted on September 3, 2025, under the Issuer's 2023 Equity Incentive Plan.
• The exercise price for these options is $1.58 per share, which matched the closing price of the company's common stock on the grant date.
• Vesting schedule dictates 25% of the options will vest on the one-year anniversary of September 3, 2025.
• The remaining 75% of the options will vest in 1/36th monthly installments, contingent on Mr. Jackson's continued service to the Issuer.
• The options have an expiration date of September 3, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event, which is generally a neutral to slightly positive signal as it aligns management incentives with shareholder interests. It does not contain information that would significantly alter the company's financial outlook or market perception.

Positives

• The grant of incentive stock options aligns the Chief Financial Officer's interests with those of shareholders, encouraging long-term performance.
• Equity compensation serves as a retention mechanism for key management personnel, ensuring continuity in leadership.
• The exercise price matching the closing price on the grant date is a standard practice for incentive grants.

Negatives

• Potential for future dilution of existing shares if the options are exercised, although this is a standard aspect of equity compensation plans.

Risks

• The value of the options is subject to the future market price fluctuations of Calidi Biotherapeutics' common stock.
• Options are subject to forfeiture if the reporting person's service to the Issuer terminates before the vesting conditions are met.

Future Outlook

The vesting schedule for the granted options extends over several years, indicating an expectation of continued service from the Chief Financial Officer and providing a long-term incentive for performance.

Industry Context

The grant of stock options to a Chief Financial Officer is a common and widely accepted practice in the biotechnology and broader corporate sectors. It is a standard component of executive compensation packages designed to attract, retain, and motivate key talent by linking their financial interests to the company's long-term stock performance.

Comparison to Industry Standards

• The use of incentive stock options as a component of executive compensation is a standard practice across various industries, including biotechnology, aligning with typical corporate governance and talent retention strategies.
• The vesting schedule, with an initial cliff vesting followed by monthly installments, is a common structure for equity awards, comparable to plans observed in companies like Moderna or BioNTech for their executives, though the specific number of options and exercise price are company-specific.

Corporate Governance

Related Party Transactions

• The grant of 30,000 incentive stock options to Andrew C. Jackson, the Chief Financial Officer, constitutes a transaction with a related party, as he is an officer of the Issuer.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized management focused on long-term company performance.
• Employees: Reinforces the company's commitment to executive compensation and retention, potentially signaling stability in leadership.
• Management: Provides a significant long-term incentive and aligns personal financial success with company growth.

Next Steps

• Continued service of the Chief Financial Officer to meet vesting conditions.
• Vesting of 25% of options on September 3, 2026.
• Monthly vesting of the remaining 75% of options over 36 months.
• Potential exercise of vested options by the Chief Financial Officer before the expiration date of September 3, 2035.

Key Dates

Recommendation

This Form 4 reports a standard equity incentive grant to a key executive, which is a common practice for aligning management interests with shareholders and retaining talent. It does not contain information that would significantly alter the investment thesis for Calidi Biotherapeutics, Inc., and therefore does not warrant a change in investment recommendation based solely on this filing.

Keywords

Calidi Biotherapeutics, CLDI, Stock Options, Equity Incentive Plan, Executive Compensation, Form 4, Andrew C. Jackson, CFO